Trial Profile
Phase II Trial of Pyrazoloacridine (PZA) in Previously Untreated Hepatocellular Carcinoma (HCC) Patients.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs PD 115934 (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 16 Sep 2010 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 05 Nov 2007 Status changed from in progress to completed.
- 15 Oct 2005 New trial record.